To help meet rising outsourcing demands and the life sciences industry’s quality concerns, American Peptide Company, a leading provider of peptides and peptide-based services to the pharmaceutical and biotech industries, has ramped up its cGMP (current Good Manufacturing Practice) peptide manufacturing capabilities as well as its service offerings. As a result, the company can rapidly provide viable peptide-based solutions to speed time-to-market while maintaining stringent production standards.   

The company’s significant expansion of its Vista, California facility allows it to process large-scale innovative peptide production needs while still meeting the high standards of GMP regulations.  The facility expansion includes three main areas: purification, synthesis and lyophilization.   Four new peptide purification suites have been added for large scale purification projects. Construction of two new synthesis suites, both for solution phase and solid phase will be planned. Finally for the lyophilization process, another capacity tray will be added to enable release of multi-Kg single batches of peptide APIs.

“As the demand for peptide-based therapies increases, we are constantly seeking ways to enhance our operations to better meet customer demands for large volumes without compromising our high standards for production.” said Takahiro Ogata, president and COO, American Peptide Company. “The BIO International Convention is an opportunity for us to share our newest innovations that illustrate how we keep pace with production needs and regulatory standards.”

In addition to the expansion of its manufacturing capabilities, American Peptide Company continues to offer the Total Peptide Management™ program as a way to provide customers with increased regulatory support and value-added services. The program offers a broad portfolio of peptides, and expert consultation to support customer needs as drug products move from discovery to development and commercialization.